GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lyra Therapeutics LYRA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.19

—

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Lyra Therapeutics — daily LYRA Delayed
Market value
$336,300
Last close × shares
Volume
401
Shares, 5 Nov 2026

About Lyra Therapeutics

Its shares trade under the ticker LYRA. It has been listed since 1 May 2020. In the fiscal year to 31 December 2025, it reported revenue of $398,000 and a net loss of $28.9m. At that date it held total assets of $36.1m and shareholders' equity of −$10.7m.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2020-05-01. The Company’s product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to locally elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically-naive CRS patients who fail medical management. The company has developed LYR-220 for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery.

Figures and description from our data supplier, not checked against the company's own report.

More about Lyra Therapeutics →

Latest on Lyra Therapeutics

Our reporting

We have not reported on Lyra Therapeutics yet.

Next results

17 Nov 2026

Due on 17 Nov 2026. Analysts expect earnings of -1.63 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Lyra Therapeutics's ticker?

Lyra Therapeutics trades as LYRA on its US listing, under ISIN US55234L2043.

What was Lyra Therapeutics's last closing price?

0.19 on 5 Nov 2026. The figure is in USD and is never converted.

When does Lyra Therapeutics next report results?

Results are expected on 17 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.